Navigation Links
New Report Analyzes Key Controversies in Multiple Sclerosis Treatment
Date:11/14/2007

SCOTTSDALE, Ariz., Nov. 14 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for MS therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Multiple Sclerosis," physician experts discuss the key controversies emerging from ECTRIMS (European Committee for Treatment and Research in MS) 2007, including:

-- Early aggressive therapy vs. more conservative approaches.

-- The negative results from REGARD, and implications for the powering of

MS trials. The report offers predictions on results expected in the

BEYOND, PreCISe and OLYMPUS.

-- The potential for pulmonary delivery of interferon and Copaxone.

-- The numerous orally available drugs in development for MS. The report

reviews the benefits and drawbacks of fingolimod, other S1Ps,

short-acting VLA4, teriflunomide, laquinimod, fampridine, fumarates and

other oral options, and predicts where they will fall on the

safety/efficacy spectrum.

-- The status and potential of a number of vaccine approaches.

-- Intriguing neuroprotection / neuroregeneration strategies, including

LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb.

Drugs/Mechanisms mentioned in this report include: S1P agonists (fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1 modulators; Epix / Amgen), inhibitors of DNA synthesis/repair (teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel blockers (fampridine; Acorda, BNC-245; Bionomics), interferons (Avonex; Biogen, Rebif; Ares-Serono, Betaseron; Bayer-Schering and Biferonex; Biopartners Holdings), VLA4 inhibitors (Tysabri; Biogen/Elan, firategrast; GlaxoSmithKline, CDP-323; UCB/Biogen; ATL1102 (Antisense Th
'/>"/>

SOURCE MedPredict Market Research
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
(Date:3/25/2015)... An increase of awareness related to benefits of ... nutrients, regulatory changes and concerns related to consumer safety ... natural astaxanthin over the past few years. Producers of ... to satisfy the rising demand. , The global ... in nutraceuticals, aqua feed, food and beverages and cosmetics) ...
(Date:3/25/2015)... 2015 Data from Evidence of ... Action in Neuromuscular Diseases , South San ... (Nasdaq: CYTK) announced the publication of a manuscript ... tirasemtiv in the journal Neurotherapeutics. This publication ... Effect” or hypothesis-generating clinical trial which evaluated tirasemtiv ...
(Date:3/25/2015)... 2015 Researchers at Ancon Medical ... that will enable broader and less invasive screening ... a simple breath screen. The Minnesota-based medical device ... and Drug Administration (FDA) approval process and is ... Nanoparticle Biomarker Tagging device. , Ancon Medicals nanoparticle ...
Breaking Biology Technology:Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... Elenore Bogoch of BioRadar UK Ltd. announced that retrospective studies ... lethal strains of E. Coli preceded the current E. Coli ... in laboratories in Germany and elsewhere since 1995, and genome ... subsequences of the genome of an infectious agent that have ...
... June 20, 2011 Genetic Technologies Limited (ASX: GTG; ... division, Phenogen Sciences Inc., has launched the new BREVAGen™ ... Phenogen Sciences will target its promotion campaign ...  The company has deployed its sales force to service ...
... , Kuros Biosurgery AG, a ... and bioactive-biomaterial,combination products for trauma, wound and spinal ... by the European Patent Office. This now allowed ... portfolio of applications,and patents designed to protect Kuros’ ...
Cached Biology Technology:Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4Kuros Announces Allowance of European Patent for Synthetic Biomaterials 2Kuros Announces Allowance of European Patent for Synthetic Biomaterials 3
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... Beta Systems today announced ... management (IAM) solution for a fixed price and ... new IAM package, customers benefit from the 30 ... IAM implementations across different industries. The new fixed-price ... any necessary services and consulting. It spans the ...
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... may help prevent potentially dangerous bacteria like Staphylococcus ... animals, scientists heard today (Monday 8 September 2008) ... being held this week at Trinity College, Dublin. ... protect them against antibiotics and the body,s natural ...
... Researchers in Switzerland have developed a new ... in microfluidic systems, these "Pyrex"-like nanoparticles are ... and harsh chemical environments than currently used ... Their introduction could extend the range of ...
... INCF Congress of Neuroinformatics will convene September 7-9 ... The emerging neuroinformatics field combines neuroscience and informatics ... understanding the structure and function of the brain. ... disorders and diseases. With a broad international outreach, ...
Cached Biology News:Milk may help bacteria survive against low levels of antibiotics 2INCF organizes the first congress dedicated to the emerging field of neuroinformatics 2